6533b86efe1ef96bd12cb5e2
RESEARCH PRODUCT
Novel Pharmaceutical and Nutraceutical-Based Approaches for Cardiovascular Diseases Prevention Targeting Atherogenic Small Dense LDL
Jelena VekicAleksandra ZeljkovicAleksandra StefanovicNatasa Bogavac-stanojevicIoannis IliasJosé Silva-nunesAnca Pantea StoianAndrej JanezRizzo Manfredisubject
lipidslipoproteinstherapycholesterol lipids lipoproteins prevention therapypreventionPharmaceutical Sciencecholesterollipids (amino acids peptides and proteins)small dense LDLdescription
Compelling evidence supports the causative link between increased levels of low-density lipoprotein cholesterol (LDL-C) and atherosclerotic cardiovascular disease (CVD) development. For that reason, the principal aim of primary and secondary cardiovascular prevention is to reach and sustain recommended LDL-C goals. Although there is a considerable body of evidence that shows that lowering LDL-C levels is directly associated with CVD risk reduction, recent data shows that the majority of patients across Europe cannot achieve their LDL-C targets. In attempting to address this matter, a new overarching concept of a lipid-lowering approach, comprising of even more intensive, much earlier and longer intervention to reduce LDL-C level, was recently proposed for high-risk patients. Another important concern is the residual risk for recurrent cardiovascular events despite optimal LDL-C reduction, suggesting that novel lipid biomarkers should also be considered as potential therapeutic targets. Among them, small dense LDL particles (sdLDL) seem to have the most significant potential for therapeutic modulation. This paper discusses the potential of traditional and emerging lipid-lowering approaches for cardiovascular prevention by targeting sdLDL particles.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2022-04-09 |